BackPacira BioSciences Overview
Pacira BioSciences Inc

Pacira BioSciences Target Price

Analysts' average 12-month price target for Pacira BioSciences is $28.

Get informed when a big investor buys or sells

+ Follow

Share Price

$24.69

Average Target Price

$27.6712.1% upside

3 analysts in the last 4 months

High: $30 | Low: $25

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-09-09Leerink Partners$2813.4% upsideOpen
2026-08-17Truist Financial$3021.5% upsideOpen
2026-08-05RBC CapitalDouglas Miehm$251.3% upsideOpen
2026-05-01Needham$3229.6% upsideOpen
2025-12-08Barclays$279.4% upsideOpen
2025-02-28Barclays$242.8% downsideOpen
2025-02-28H.C. Wainwright$4894.4% upsideOpen
2025-01-30Truist FinancialLes Sulewski$251.3% upsideOpen
2024-11-07Piper SandlerDavid Amsellem$1251.4% downsideOpen
2024-09-24JefferiesGlen Santangelo$1827.1% downsideOpen
2024-08-13Truist FinancialLes Sulewski$867.6% downsideOpen
2024-07-02H.C. WainwrightOren Livnat$57130.9% upsideOpen
2024-06-13JefferiesGlen Santangelo$3645.8% upsideOpen
2024-05-21Piper SandlerDavid Amsellem$4270.1% upsideOpen
2023-01-06BMO Capital$52110.6% upsideOpen
2023-01-06Needham$63155.2% upsideOpen

Pacira BioSciences (PCRX) FAQ

Pacira BioSciences's target price stands at $28. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $28 for PCRX implies 12.1% upside versus today's price ($24.69). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Pacira BioSciences's target price evolved across reporting periods, while the comparison chart places PCRX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Pacira BioSciences's reading of $28 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.